Recently, the Department of Justice (DOJ) has intervened in five anti-kickback lawsuits against Insys Therapeutics, Inc. (Insys), the manufacturer of Fentanyl. In 2012, Insys received approval from the Food and Drug Administration (FDA) for Fentanyl to treat persistent breakthrough pain in adult cancer patients who developed tolerance toward around-the-clock opioid therapy. It is a spray [ ]
http://www.healthcarelawfirm.net/2018/05/31/opioid-kickbacks-fueling-epidemic/
No comments:
Post a Comment